Trials / Completed
CompletedNCT01213433
Amodiaquine+Artesunate for Uncomplicated Malaria Treatment
Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Centre Muraz · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
This is a phase IV one-arm study aiming at recruiting 50 patients to assess the efficacy of AQ+AS in patients with a positive RDT diagnosis of malaria in Nanoro, Burkina Faso.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Artesunate-Amodiaquine | Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg) |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2010-11-01
- Completion
- 2011-04-01
- First posted
- 2010-10-04
- Last updated
- 2015-07-31
Locations
1 site across 1 country: Burkina Faso
Source: ClinicalTrials.gov record NCT01213433. Inclusion in this directory is not an endorsement.